Anika Therapeutics, Inc.

Overview

Anika develops and commercializes hyaluronic acid (HA)–based products for osteoarthritis (OA) pain management and regenerative orthopedic solutions. The company’s mission is to restore active living, empower surgeon choice, and improve patient outcomes worldwide. Core values include Trust & Respect, Quality, Empowerment & Teamwork, and Focus.

Key facts

• Employees: 235 full-time employees in the United States and Europe (as of December 31, 2025).
• International exposure: 38% of product sales were to international customers in 2025.
• Revenue concentration: Johnson & Johnson MedTech accounted for 50% of Anika’s revenue in 2025.
• Major divestitures:
  • Arthrosurface Incorporated — completed October 31, 2024; consideration included a $7.0 million ten-year non-interest bearing promissory note plus potential revenue payments and a buy-out payment.
  • Parcus Medical, LLC — completed March 7, 2025; cash payment of $4.5 million at closing (subject to post-closing adjustments).
• R&D spend:
  • 2025: $25.8 million
  • 2024: $25.5 million
  • 2023: $21.8 million

Product development and regulatory milestones

• Hyalofast
  • PMA filed with the U.S. FDA on October 31, 2025.
  • FDA issued a deficiency letter in January 2026.
  • Hyalofast is a single-stage, off-the-shelf cartilage repair therapy currently sold outside the United States.
  • FastTRACK Phase III topline results announced July 2025; the trial did not meet co-primary endpoints but showed consistent improvements versus microfracture across multiple measures.
• Cingal
  • U.S. NDA activities ongoing with heightened FDA engagement since a 2023 Type-C meeting.
  • CE-marked and sold in over 50 countries outside the U.S.; U.S. approval is in process.
• Integrity Implant System
  • FDA clearance for U.S. commercial use in August 2023.
  • Limited market release began November 2023 with strong growth and adoption by new customers.

Manufacturing

• All HA-based products are manufactured at the Bedford, Massachusetts facility.
• Ongoing investments are focused on expanding capacity to meet growing demand.

Sales model and channels

• OA Pain Management (Monovisc, Orthovisc, Cingal)
  • In the U.S., Monovisc and Orthovisc are marketed exclusively by J&J MedTech under long-term licensing and manufacturing agreements; J&J MedTech handles marketing and end-user sales in the U.S.
  • Extensions of exclusivity have been negotiated (Monovisc extended through December 2031; Orthovisc through December 2028 and potentially beyond).
• Regenerative Solutions and certain non-orthopedic products
  • Sold directly to clinicians (hospitals and ASCs) in the U.S. with a hybrid approach that includes independent distributors.
  • International sales are largely through a network of distributors.
• Non-orthopedic products (Hyvisc, Hyalobarrier, Anikavisc, Nuvisc) are sold through commercial partners globally.

Markets and commercial outlook

• 38% of product sales were international in 2025.
• The company continues global expansion for Regenerative Solutions and non-orthopedic lines while relying on U.S. channels and the U.S. payer environment for a large portion of revenue.

Regulatory and compliance

• Devices: Manages Class I–III device pathways, 510(k) clearances, and PMA processes; navigating EU MDR transition and UKCA requirements.
• Drugs/Biologics: Pursues NDA pathways where applicable; Hyalofast and Cingal are in various regulatory stages.
• Data protection: Ongoing compliance with GDPR/UK GDPR, CCPA/CPRA, vendor risk management, and cybersecurity requirements.

Intellectual property and competition

• IP strategy includes patents, trademarks, trade secret protection, and evaluation of third-party licenses. The company recognizes potential challenges to patent scope and may need to license third-party technology.
• Competitors include large pharmaceutical and medical device companies across OA and regenerative segments (examples: Sanofi Genzyme, Zimmer Biomet, Bioventus, Avanos, Pacira, ConMed, Ferring; Arthrex, Smith & Nephew, Stryker, Zimmer Biomet). Anika highlights leadership in Monovisc/Orthovisc (U.S.) and growth in Integrity and Hyalofast.

Product and segment details

• OA Pain Management
  • Monovisc and Orthovisc: HA viscosupplements for OA-related pain relief; U.S. rights marketed by J&J MedTech under exclusive licensing; international distribution via direct and partner channels.
  • Cingal: Single-injection HA combined with a fast-acting steroid; CE-marked and sold internationally; U.S. regulatory work ongoing.
• Regenerative Solutions
  • Integrity Implant System: HA-based scaffold with bone/tendon fixation components for arthroscopic delivery; designed for rotator cuff and other tendon repairs.
  • Hyalofast: 100% HA scaffold for single-stage cartilage regeneration; marketed outside the U.S. with a PMA filed in 2025.
  • Tactoset: HA-enhanced injectable bone substitute for fracture repair and hardware augmentation.
• Non-Orthopedic Products
  • Hyvisc: Veterinary HA product for equine OA.
  • Hyalobarrier: Anti-adhesion barrier for abdominal-pelvic surgeries.
  • Ophthalmic HA products: Anikavisc and Nuvisc for ophthalmic procedures.

Recent strategic actions and outlook

• Strategic focus announced October 2024 to concentrate on OA Pain Management and Regenerative Solutions; completed divestitures of Arthrosurface (2024) and Parcus (2025).
• U.S. regulatory pathway activities continue for Hyalofast and Cingal, with ongoing engagement with the FDA.
• International growth continues for OA Pain Management products and selected regenerative offerings.
• R&D efforts remain focused on extending HA technologies across shoulder, knee, and foot-and-ankle applications and protecting IP while pursuing partnerships.

In short

Anika Therapeutics concentrates on HA-based products for OA pain management and regenerative orthopedic care, manufacturing in Bedford, MA and selling through a mix of exclusive partnerships, direct sales, and a global distributor network. The company is streamlining its portfolio around core HA platforms, advancing U.S. regulatory filings for Hyalofast and Cingal, and growing international sales. As of year-end 2025, Anika employed 235 people in the U.S. and Europe, with international product sales representing 38% of product revenue and J&J MedTech accounting for 50% of total revenue.